8-K current report · filed Sep 1, 2026

Adicet Bio Inc (ACET) 8-K Current Report: September 1, 2026

Item EX-99.1Item 7.01ACET overview

Short answer

Adicet Bio Inc (ACET) filed an 8-K current report with the SEC on September 1, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Adicet completed the last patient visit for planned prula-cel analysis in systemic lupus erythematosus.

Adicet Bio Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Adicet completed the last patient visit for planned prula-cel analysis in systemic lupus erythematosus
  • Study includes patients with and without lupus nephritis
  • Upcoming analysis represents a clinical catalyst for prula-cel, formerly ADI-001
  • Corporate update details available in Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • Prula-cel SLE/LN analysis completed, covering 22 patients with minimum 6-month follow-up and 13 with at least 12 months
  • Topline prula-cel data expected September 2026, the key near-term catalyst for efficacy, safety and potential pivotal-trial planning
  • FDA cleared ADI-212 IND for mCRPC, with Phase 1 enrollment targeted for 4Q 2026
  • Outpatient prula-cel administration expanded following FDA alignment, potentially improving trial execution and treatment scalability
  • First in vivo CAR-T candidate expected to enter clinical development in 2H 2027, extending the company’s longer-term pipeline beyond cell therapy programs

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Adicet Bio Inc 8-K filings

Get the next ACET 8-K as it lands

Follow ACET for push alerts, or ask the research agent what this filing means.